<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03823144</url>
  </required_header>
  <id_info>
    <org_study_id>18-010370</org_study_id>
    <nct_id>NCT03823144</nct_id>
  </id_info>
  <brief_title>Intravital Microscopy in Human Solid Tumors</brief_title>
  <official_title>Intravital Microscopy (IVM) in Human Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the tumor-associated vasculature of patients with solid tumors.
      The investigators will use a technology known as intravital microscopy (IVM) in order to
      visualize in real-time the vessels associated with solid tumors. The IVM observations may
      determine if an individual patient's tumor vessels would be amenable to receiving systemic
      therapy, based on the functionality of the vessels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective(s): To determine the feasibility and clinical utility of performing HIVM in
      patients with solid tumors during standard course of treatment (surgical resection).

      Secondary objective(s):

        1. Compare the microscopic observation of the tumor-associated vessels with normal tissue
           (e.g. peritoneal surface) in each individual subject.

        2. Correlate the microscopic observations of the tumor-associated vessels with pathologic
           grade of tumor.

        3. To correlate the microscopic observation of the microvasculature with tumor-specific and
           overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label, non-randomized, single center, study of IVM observation in conjunction with fluorescein in subjects with solid tumors undergoing surgical resection.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>1. Tumor vessel identification (# tumor vessels visualized per high power field)</measure>
    <time_frame>12-15 minutes</time_frame>
    <description>Identify and measure vessels associated with solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Tumor vessel density (# tumor vessels per square cm area observed)</measure>
    <time_frame>12-15 minutes</time_frame>
    <description>Determine vessel density per 10x field</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3. Fluorescent dye uptake (# tumor vessels with fluorescent dye uptake and # tumor vessels without dye uptake)</measure>
    <time_frame>12-15 minutes</time_frame>
    <description>Visualize vital dye within the vessels (fluorescein)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>4. Tumor blood flow (velocity, mm/sec)</measure>
    <time_frame>12-15 minutes</time_frame>
    <description>Calculate the blood flow velocity of the vessels and tissue penetration of fluorescent dye as a marker of vessel permeability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5. Post-operative comparison of the microvasculature of tumor with normal tissue</measure>
    <time_frame>15-20 minutes</time_frame>
    <description>Post-operative comparison of the microvasculature of tumor with normal tissue (e.g. peritoneum) in each individual subject using vessel diameters, vessel density, detection of intravital dye and flow rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6. Post-operative correlation of the microvasculature with pathologic features of the tumor implants (i.e. tumor grade) at the time of the final pathology report (5-7 days after surgery).</measure>
    <time_frame>5-7 days</time_frame>
    <description>The investigators will determine if there is a correlation between the microvasculature with pathologic features of the tumor implants (i.e. tumor grade) at the time of the final pathology report (5-7 days after surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative correlation of the microscopic observation of the tumor microvasculature tumor-specific and overall survival.</measure>
    <time_frame>5 years</time_frame>
    <description>The investigators will determine if there is a correlation between the microscopic observation of the tumor microvasculature tumor-specific and overall survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with solid tumors during surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Human Intravital Microscopy</intervention_name>
    <description>Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years of age.

          2. ECOG Performance Status of ≤ 2.

          3. Measurable tumor by direct visualization requiring surgical resection in the OR.

          4. Tumor types of origin include gastric, pancreatic, hepatobiliary, colorectal, and
             sarcoma. Tumors may be primary or metastatic to solid or hollow intra-abdominal
             organs.

          5. Subject must understand the investigational nature of this study and sign an
             Independent Ethics Committee/Institutional Review Board approved written informed
             consent.

          6. Subject must have a skin prick test pre-operatively (at the time of the preoperative
             visit and after signed informed consent for entry into this clinical trial is given)
             to determine any sensitivity to fluorescein.

        Exclusion Criteria:

          1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations.

          2. Renal dysfunction as defined as a GFR &lt; 45.

          3. Liver dysfunction as defined by Child-Pugh score &gt; 5, or LFT's 1.5x above normal
             range.

          4. Any known allergy or prior reaction to fluorescein or a positive skin prick test to
             fluorescein.

          5. Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy
             test.

          6. Unwilling or unable to follow protocol requirements.

          7. Any condition which in the Investigators' opinion deems the patient unsuitable (e.g.,
             abnormal EKG, including T wave inversion, elevated T waves, prolonged QRS interval, or
             conduction blocks) or that requires further work-up (including cardiac echo or stress
             test).

          8. Any condition that excludes surgery as the standard of care (e.g. high disease burden
             where alternative treatments like systemic chemotherapy would be preferred).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel M Gabriel, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel M Gabriel, M.D., Ph.D.</last_name>
    <phone>904-953-2523</phone>
    <email>gabriel.emmanuel@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael B Wallace, M.D.</last_name>
    <phone>904-953-2221</phone>
    <email>wallace.michael@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel M Gabriel, M.D., Ph. D.</last_name>
      <phone>904-953-2523</phone>
      <email>gabriel.emmanuel@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Emmanuel M Gabriel, M.D., Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael B Wallace, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, Vardam TD, Weis EL, Passanese J, Wang WC, Gollnick SO, Dewhirst MW, Rose-John S, Repasky EA, Baumann H, Evans SS. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest. 2011 Oct;121(10):3846-59. doi: 10.1172/JCI44952. Epub 2011 Sep 19.</citation>
    <PMID>21926464</PMID>
  </results_reference>
  <results_reference>
    <citation>Fisher DT, Muhitch JB, Kim M, Doyen KC, Bogner PN, Evans SS, Skitzki JJ. Intraoperative intravital microscopy permits the study of human tumour vessels. Nat Commun. 2016 Feb 17;7:10684. doi: 10.1038/ncomms10684.</citation>
    <PMID>26883450</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010 Apr;36(3):321-31. doi: 10.1055/s-0030-1253454. Epub 2010 May 20. Review.</citation>
    <PMID>20490982</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12. Review.</citation>
    <PMID>20061178</PMID>
  </results_reference>
  <results_reference>
    <citation>Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010 Apr;17(3):206-25. doi: 10.1111/j.1549-8719.2010.00029.x. Review.</citation>
    <PMID>20374484</PMID>
  </results_reference>
  <results_reference>
    <citation>Skitzki JJ, Chen Q, Wang WC, Evans SS. Primary immune surveillance: some like it hot. J Mol Med (Berl). 2007 Dec;85(12):1361-7. Epub 2007 Aug 18. Review.</citation>
    <PMID>17704903</PMID>
  </results_reference>
  <results_reference>
    <citation>Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002 Apr;2(4):266-76. Review.</citation>
    <PMID>12001988</PMID>
  </results_reference>
  <results_reference>
    <citation>Murooka TT, Mempel TR. Multiphoton intravital microscopy to study lymphocyte motility in lymph nodes. Methods Mol Biol. 2012;757:247-57. doi: 10.1007/978-1-61779-166-6_16.</citation>
    <PMID>21909917</PMID>
  </results_reference>
  <results_reference>
    <citation>Entenberg D, Kedrin D, Wyckoff J, Sahai E, Condeelis J, Segall JE. Imaging tumor cell movement in vivo. Curr Protoc Cell Biol. 2013 Mar;Chapter 19:Unit19.7. doi: 10.1002/0471143030.cb1907s58.</citation>
    <PMID>23456602</PMID>
  </results_reference>
  <results_reference>
    <citation>McLaughlin RA, Scolaro L, Robbins P, Hamza S, Saunders C, Sampson DD. Imaging of human lymph nodes using optical coherence tomography: potential for staging cancer. Cancer Res. 2010 Apr 1;70(7):2579-84. doi: 10.1158/0008-5472.CAN-09-4062. Epub 2010 Mar 16.</citation>
    <PMID>20233873</PMID>
  </results_reference>
  <results_reference>
    <citation>Patsialou A, Bravo-Cordero JJ, Wang Y, Entenberg D, Liu H, Clarke M, Condeelis JS. Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors. Intravital. 2013 Apr 1;2(2):e25294.</citation>
    <PMID>25013744</PMID>
  </results_reference>
  <results_reference>
    <citation>Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12.</citation>
    <PMID>22162570</PMID>
  </results_reference>
  <results_reference>
    <citation>Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D; French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010 Dec 15;116(24):5608-18. doi: 10.1002/cncr.25356. Epub 2010 Aug 24.</citation>
    <PMID>20737573</PMID>
  </results_reference>
  <results_reference>
    <citation>Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010 Jan 1;28(1):63-8. doi: 10.1200/JCO.2009.23.9285. Epub 2009 Nov 16. Erratum in: J Clin Oncol. 2010 Apr 1;28(10):1808.</citation>
    <PMID>19917863</PMID>
  </results_reference>
  <results_reference>
    <citation>Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D; Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010 Sep;17(9):2370-7. doi: 10.1245/s10434-010-1039-7. Epub 2010 Mar 25.</citation>
    <PMID>20336386</PMID>
  </results_reference>
  <results_reference>
    <citation>Kalogeromitros DC, Makris MP, Aggelides XS, Mellios AI, Giannoula FC, Sideri KA, Rouvas AA, Theodossiadis PG. Allergy skin testing in predicting adverse reactions to fluorescein: a prospective clinical study. Acta Ophthalmol. 2011 Aug;89(5):480-3. doi: 10.1111/j.1755-3768.2009.01722.x. Epub 2009 Nov 10.</citation>
    <PMID>19906081</PMID>
  </results_reference>
  <results_reference>
    <citation>Jaffer FA. Intravital fluorescence microscopic molecular imaging of atherosclerosis. Methods Mol Biol. 2011;680:131-40. doi: 10.1007/978-1-60761-901-7_9.</citation>
    <PMID>21153378</PMID>
  </results_reference>
  <results_reference>
    <citation>Munn LL, Padera TP. Imaging the lymphatic system. Microvasc Res. 2014 Nov;96:55-63. doi: 10.1016/j.mvr.2014.06.006. Epub 2014 Jun 21. Review.</citation>
    <PMID>24956510</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolfe DR. Fluorescein angiography basic science and engineering. Ophthalmology. 1986 Dec;93(12):1617-20.</citation>
    <PMID>3808620</PMID>
  </results_reference>
  <results_reference>
    <citation>Bloom JN, Herman DC, Elin RJ, Sliva CA, Ruddel ME, Nussenblatt RB, Palestine AG. Intravenous fluorescein interference with clinical laboratory tests. Am J Ophthalmol. 1989 Oct 15;108(4):375-9.</citation>
    <PMID>2801858</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Emmanuel M. Gabriel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03823144/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03823144/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

